MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment

Critical Reviews in Oncology/Hematology 2015 August 22 [Epub ahead of print] [Link]

Urso L, Calabrese F, Favaretto A, Conte P, Pasello G.

Abstract

The tumor suppressor p53 regulates genes involved in DNA repair, metabolism, cell cycle arrest, apoptosis and senescence. p53 is mutated in about 50% of the human cancers, while in tumors with wild-type p53 gene, the protein function may be lost because of overexpression of Murine Double Minute 2 (MDM2). MDM2 targets p53 for ubiquitylation and proteasomal degradation. p53 reactivation through MDM2 inhibitors seems to be a promising strategy to sensitize p53 wild-type cancer cells to apoptosis. Moreover, additional p53-independent molecular functions of MDM2, such as neoangiogenesis promotion, have been suggested. Thus, MDM2 might be a target for anticancer treatment because of its antiapoptotic and proangiogenetic role. Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related tumor where wild-type p53 might be present. The present review gives a complete landscape about the role of MDM2 in cancer pathogenesis, prognosis and treatment, with particular focus on Malignant Pleural Mesothelioma.

Both comments and trackbacks are currently closed.